JP2022520986A5 - - Google Patents
Info
- Publication number
- JP2022520986A5 JP2022520986A5 JP2021548688A JP2021548688A JP2022520986A5 JP 2022520986 A5 JP2022520986 A5 JP 2022520986A5 JP 2021548688 A JP2021548688 A JP 2021548688A JP 2021548688 A JP2021548688 A JP 2021548688A JP 2022520986 A5 JP2022520986 A5 JP 2022520986A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- modified
- sugar moiety
- modified oligonucleotide
- oligomer compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809492P | 2019-02-22 | 2019-02-22 | |
| US62/809,492 | 2019-02-22 | ||
| PCT/US2020/019272 WO2020172559A1 (en) | 2019-02-22 | 2020-02-21 | Compounds and methods for reducing atxn3 expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520986A JP2022520986A (ja) | 2022-04-04 |
| JP2022520986A5 true JP2022520986A5 (https=) | 2023-03-02 |
Family
ID=72143504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548688A Pending JP2022520986A (ja) | 2019-02-22 | 2020-02-21 | Ａｔｘｎ３発現を減少させるための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220195431A1 (https=) |
| EP (1) | EP3927827A4 (https=) |
| JP (1) | JP2022520986A (https=) |
| WO (1) | WO2020172559A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190104A1 (ar) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
| EP4663758A3 (en) | 2018-05-09 | 2026-04-29 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing atxn3 expression |
| CN113950529A (zh) * | 2019-06-06 | 2022-01-18 | 豪夫迈·罗氏有限公司 | 靶向atxn3的反义寡核苷酸 |
| JP7776420B2 (ja) | 2020-05-12 | 2025-11-26 | 田辺三菱製薬株式会社 | Ａｔａｘｉｎ ３発現を調節するための化合物、方法及び医薬組成物 |
| AR124229A1 (es) | 2020-12-03 | 2023-03-01 | Hoffmann La Roche | Oligonucleótidos antisentido que actúan sobre atxn3 |
| US20230060373A1 (en) | 2020-12-03 | 2023-03-02 | Hoffmann-La Roche Inc. | Antisense Oligonucleotides Targeting ATXN3 |
| US20240336915A1 (en) * | 2021-01-22 | 2024-10-10 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing dux4 expression |
| WO2025252669A1 (en) | 2024-06-03 | 2025-12-11 | Evotec International Gmbh | Modified oligonucleotides for reducing atxn3 expression |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1268856A2 (de) * | 2000-04-07 | 2003-01-02 | Epigenomics AG | Detektion von snp's und cytosin-methylierungen |
| US8178503B2 (en) * | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| US20150315595A1 (en) * | 2012-03-12 | 2015-11-05 | Santaris Pharma A/S | Compositions and Methods for Modulation of ATXN3 Expression |
| EP4285912A3 (en) * | 2015-09-25 | 2024-07-10 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
| WO2018002886A1 (en) * | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia 3 (sca3) and other related disorders |
| EP4663758A3 (en) * | 2018-05-09 | 2026-04-29 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing atxn3 expression |
-
2020
- 2020-02-21 WO PCT/US2020/019272 patent/WO2020172559A1/en not_active Ceased
- 2020-02-21 EP EP20758529.0A patent/EP3927827A4/en active Pending
- 2020-02-21 JP JP2021548688A patent/JP2022520986A/ja active Pending
- 2020-02-21 US US17/432,237 patent/US20220195431A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022520986A5 (https=) | ||
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP2022515193A5 (https=) | ||
| US5744460A (en) | Combination for treatment of proliferative diseases | |
| JP2022518929A5 (https=) | ||
| JP2024081668A5 (https=) | ||
| JP2025165939A5 (https=) | ||
| JP7258773B2 (ja) | α－１アンチトリプシン（ＡＡＴ）ＲＮＡｉ剤、ＡＡＴ ＲＮＡｉ剤を含む組成物、及び使用方法。 | |
| JP2024028749A5 (https=) | ||
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2021530204A5 (https=) | ||
| JP2021533804A5 (https=) | ||
| JP2023518409A5 (https=) | ||
| JPWO2022270585A5 (https=) | ||
| JP2022533358A5 (https=) | ||
| JP2019525918A5 (https=) | ||
| JP2024516356A5 (https=) | ||
| EP1141278B1 (en) | Therapeutic pde4d phosphodiesterase inhibitors | |
| JP2023536472A5 (https=) | ||
| JP2023539341A5 (https=) | ||
| TW201919654A (zh) | 用於抑制α-ENaC表現之RNAi試劑及使用方法 | |
| JP2024504377A5 (https=) | ||
| JP2022527105A5 (https=) | ||
| JP2023536994A5 (https=) | ||
| JP2024540537A5 (https=) |